Profusa Secures $100M Equity Facility for Bitcoin Buys Post-Merger

TL;DR

**Profusa's $100M equity line for Bitcoin buys is a high-risk gamble, signaling potential desperation or an unconventional treasury strategy that could either pay off big or burn investors.**

AI Summary

Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination on July 11, 2025, becoming a wholly-owned subsidiary of the Company. The company, incorporated in California on May 11, 2009, is focused on developing biointegrated sensors, including the Lumee Oxygen Platform for tissue oxygen monitoring in the EU and the Lumee Glucose Platform for continuous glucose monitoring. On July 28, 2025, Profusa entered into a Purchase Agreement with Ascent Partners Fund LLC, allowing Profusa to sell up to $100,000,000 in common stock to Ascent over 36 months. This includes up to 8,070,830 Purchase Shares and 900,000 Commitment Warrant Shares. The purchase price for these shares will be 97% of the lowest volume-weighted average price during a valuation period, subject to a floor price and a maximum of $5,000,000 or 100% of the average daily traded value for the preceding five days per closing. The company's common stock is listed on the Nasdaq Global Market under 'PFSA' and traded at $0.53 per share on August 5, 2025. Proceeds from these sales are intended for Bitcoin purchases, which can be used for debt repayment.

Why It Matters

This S-1/A filing reveals Profusa's strategy to secure up to $100,000,000 in capital through an equity facility with Ascent Partners Fund LLC, a significant move for a company focused on biointegrated sensors. The stated use of proceeds for Bitcoin purchases, which can then be used for debt repayment, introduces an unconventional and potentially high-risk financial strategy for investors. This could impact investor confidence and the company's valuation, especially given its current share price of $0.53 and its status as a 'smaller reporting company.' Competitors in the medical device and continuous glucose monitoring space, such as Dexcom or Abbott, typically rely on more traditional financing and reinvestment into R&D, making Profusa's approach a notable outlier.

Risk Assessment

Risk Level: high — The risk level is high due to the stated intention to use proceeds from the $100,000,000 equity facility for 'the purchase of Bitcoin (which can be used for debt repayment).' This introduces significant cryptocurrency market volatility risk to the company's balance sheet. Additionally, the company's stock traded at a low $0.53 per share on August 5, 2025, and the equity facility allows sales at 97% of the lowest VWAP, indicating potential for substantial dilution for existing shareholders.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Profusa's financial health and strategic rationale for Bitcoin investments. Given the potential for significant dilution from the committed equity facility and the inherent volatility of cryptocurrency, a 'wait and see' approach is advisable, monitoring the company's actual Bitcoin acquisition and debt repayment activities before considering an investment.

Key Numbers

• $100,000,000 — Maximum Aggregate Purchase Price (Potential gross proceeds from sales of common stock to Ascent)
• 8,970,830 — Shares Offered by Selling Stockholder (Total shares Ascent may sell, including Purchase Shares and Commitment Warrant Shares)
• $0.53 — Common Stock Price (Last sale price on Nasdaq Global Market as of August 5, 2025)
• 97% — Purchase Price Discount (Percentage of lowest VWAP at which Ascent will purchase shares)
• 36 months — Purchase Agreement Term (Period over which Profusa may elect to sell shares to Ascent)
• 900,000 — Commitment Warrant Shares (Shares issuable upon exercise of warrants issued to Ascent)
• 6,554,496 — Exchange Cap Shares (Maximum shares issuable under Nasdaq rules without stockholder approval (19.9% of outstanding))
• 9.99% — Beneficial Ownership Limitation (Maximum percentage of outstanding shares Ascent can beneficially own)
• $0.01 — Commitment Warrant Exercise Price (Exercise price for the Commitment Warrants)
• $5,000,000 — Maximum Single Closing Purchase (Limit on the aggregate purchase price at any single closing)

Key Players & Entities

• Profusa, Inc. (company) — Registrant and developer of biointegrated sensors
• NorthView Acquisition Corporation (company) — Former name of Profusa, Inc. before business combination
• Ascent Partners Fund LLC (company) — Selling Stockholder and counterparty to the Purchase Agreement
• Ben C. Hwang (person) — Chief Executive Officer of Profusa, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1/A filing
• $100,000,000 (dollar_amount) — Maximum aggregate gross proceeds from sales to Ascent
• $0.53 (dollar_amount) — Last sale price for Profusa common stock on August 5, 2025
• 8,970,830 (dollar_amount) — Total shares of Common Stock offered for resale by Ascent
• 97% (dollar_amount) — Purchase price percentage of lowest VWAP for shares sold to Ascent
• Nasdaq Global Market (regulator) — Stock exchange where Profusa's common stock is listed

FAQ

Risk Factors

• Reliance on Committed Equity Facility [high — financial]: Profusa has entered into a $100,000,000 common stock purchase agreement with Ascent Partners Fund LLC. The company can sell up to $100,000,000 in common stock over 36 months. The purchase price is 97% of the lowest VWAP during a valuation period, subject to a floor price and daily purchase limits. This facility introduces dilution risk and potential for unfavorable pricing if the stock price declines significantly.
• Product Development and Commercialization Risks [high — operational]: The company is developing biointegrated sensors, including the Lumee Oxygen Platform and Lumee Glucose Platform. Success depends on regulatory approvals, market adoption, and competition. Significant investment is required for R&D, manufacturing, and sales, with no guarantee of commercial success.
• Regulatory Approval and Compliance [high — regulatory]: The Lumee Oxygen Platform requires CE Mark approval for the EU market, and the Lumee Glucose Platform will require FDA approval for the US market. Delays or failures in obtaining these approvals, or ongoing compliance issues, could materially impact the company's ability to generate revenue.
• Market Acceptance and Competition [medium — market]: The market for continuous glucose monitoring and tissue oxygen monitoring is competitive. Profusa must demonstrate the superiority of its technology and gain market acceptance against established players. Failure to achieve widespread adoption could limit revenue growth.
• Use of Proceeds for Bitcoin Purchases [high — financial]: Proceeds from the Ascent equity facility are intended for Bitcoin purchases, which can then be used for debt repayment. This strategy introduces significant volatility and risk associated with Bitcoin price fluctuations, impacting the company's financial stability and ability to manage debt effectively.
• Potential for Litigation [medium — legal]: As a publicly traded company, Profusa faces the risk of securities litigation, especially given the recent business combination and the nature of the equity financing. Such litigation could be costly and divert management attention.

Industry Context

Profusa operates in the rapidly growing medical device market, specifically focusing on biointegrated sensors for continuous physiological monitoring. Key segments include tissue oxygen monitoring and continuous glucose monitoring, driven by increasing demand for personalized healthcare, remote patient monitoring, and proactive disease management. The competitive landscape features established players and innovative startups, necessitating strong technological differentiation and efficient commercialization strategies.

Regulatory Implications

Profusa's products face significant regulatory hurdles. The Lumee Oxygen Platform requires CE Mark approval for the European market, while the Lumee Glucose Platform will need FDA approval for the US market. Navigating these complex regulatory pathways, ensuring ongoing compliance, and managing post-market surveillance are critical for market access and commercial success.

What Investors Should Do

1. Monitor Bitcoin Price Volatility
2. Evaluate Dilution Risk from Equity Facility
3. Track Product Development and Regulatory Milestones
4. Analyze Competitive Landscape and Market Penetration

Key Dates

• 2025-07-11: Completion of Business Combination — Profusa, Inc. became a wholly-owned subsidiary of the Company (formerly NorthView Acquisition Corporation), marking its transition to a publicly traded entity.
• 2025-07-28: Purchase Agreement with Ascent Partners Fund LLC — Established a committed equity facility allowing Profusa to sell up to $100,000,000 in common stock over 36 months, providing potential capital but also introducing dilution and pricing risks.
• 2025-08-05: Common Stock Trading at $0.53 — Indicates the current market valuation of the company's stock on the Nasdaq Global Market, relevant for pricing under the Ascent equity facility.

Glossary

Biointegrated Sensors

Devices designed to be integrated with biological systems to monitor physiological parameters. (This is the core technology Profusa is developing, aiming to provide real-time health data.)

Lumee Oxygen Platform

Profusa's product for monitoring tissue oxygen levels, intended for use in the EU. (Represents one of the company's key product lines and its initial market entry strategy.)

Lumee Glucose Platform

Profusa's product for continuous glucose monitoring, targeting the US market. (Represents another key product line with significant market potential, subject to FDA approval.)

Committed Equity Facility

An agreement where a company can sell shares of its stock to an investor at predetermined terms over a specified period. (The agreement with Ascent Partners Fund LLC provides Profusa with potential access to capital but also carries risks of dilution and unfavorable pricing.)

Volume-Weighted Average Price (VWAP)

The average price of a security over a given period, weighted by the volume of trades at each price level. (Used as a benchmark for determining the purchase price of shares under the Ascent equity facility, aiming for a price close to market rates.)

Commitment Warrant Shares

Shares that can be issued upon exercise of warrants granted to the investor as part of the equity facility agreement. (These represent potential future dilution for existing shareholders and are part of the overall cost of the financing.)

Exchange Cap Shares

The maximum number of shares that can be issued without triggering a shareholder vote requirement under Nasdaq listing rules (typically 19.9% of outstanding shares). (This limits the immediate dilution from certain issuances and may require shareholder approval for larger capital raises.)

Year-Over-Year Comparison

As this appears to be an initial S-1/A filing following a business combination, a direct comparison to a prior year's filing is not applicable. However, the filing outlines the company's transition to public markets, its strategic financing through a committed equity facility with Ascent Partners Fund LLC, and its product development pipeline. Key risks highlighted include reliance on this financing, product commercialization challenges, and the novel strategy of using proceeds for Bitcoin purchases.

Key Financial Figures

• $0.0001 — 0 shares of our Common Stock, par value $0.0001 per share ("the Common Stock"), by Asce
• $0.01 — ment Warrants have an exercise price of $0.01 and may be exercised for cash or, if at
• $100,000,000 — ckholder. However, we may receive up to $100,000,000 in aggregate gross proceeds under the P
• $0.53 — eported on the Nasdaq Global Market was $0.53 per share. We are a "smaller reportin
• $5,000,000 — Closing is limited to the lower of (a) $5,000,000 or (b) 100% of the average daily traded
• $0.68 — se Agreement, if any, equals or exceeds $0.68 per share (representing the lower of (a
• $30,000 — ts Agreement in an amount not to exceed $30,000 upon our execution of the Purchase Agre
• $0 — an assumed purchase price per share of $0.68, representing the closing sale price
• $5.5 million — 25, we would only receive approximately $5.5 million in aggregate gross proceeds from the sa

Filing Documents

• ea0251811-03.htm (S-1/A) — 12835KB
• ea025181103ex23-1_profusa.htm (EX-23.1) — 2KB
• ea025181103ex23-2_profusa.htm (EX-23.2) — 2KB
• tprofusa_logo.jpg (GRAPHIC) — 85KB
• timage_001.jpg (GRAPHIC) — 255KB
• timage_002.jpg (GRAPHIC) — 300KB
• timage_003.jpg (GRAPHIC) — 336KB
• timage_004.jpg (GRAPHIC) — 569KB
• timage_005.jpg (GRAPHIC) — 202KB
• timage_006.jpg (GRAPHIC) — 368KB
• timage_007.jpg (GRAPHIC) — 260KB
• timage_008.jpg (GRAPHIC) — 631KB
• 0001213900-25-079829.txt ( ) — 46750KB
• ck0001859807-20250630.xsd (EX-101.SCH) — 138KB
• ck0001859807-20250630_cal.xml (EX-101.CAL) — 77KB
• ck0001859807-20250630_def.xml (EX-101.DEF) — 796KB
• ck0001859807-20250630_lab.xml (EX-101.LAB) — 1068KB
• ck0001859807-20250630_pre.xml (EX-101.PRE) — 806KB
• ea0251811-03_htm.xml (XML) — 8788KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 72 THE COMMITTED EQUITY FACILITY 73

USE OF PROCEEDS

USE OF PROCEEDS 79 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 80 DIVIDEND POLICY 94 MARKET INFORMATION 95

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 96

BUSINESS

BUSINESS 108 MANAGEMENT 134

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 139

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 141 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 143 SELLING STOCKHOLDER 147 PLAN OF DISTRIBUTION 149

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 153 LEGAL MATTERS 157 EXPERTS 157 WHERE YOU CAN FIND MORE INFORMATION 157 INDEX TO FINANCIAL INFORMATION F-1 You should rely only on the information contained in this prospectus or any amendment or supplement to this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus or any amendment or supplement to this prospectus. Neither we nor the Selling Stockholder take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus or any amendment or supplement to this prospectus. The information in this prospectus or any amendment or supplement to this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any amendment or supplement to this prospectus, as applicable, or any sale of the securities offered by this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States: The Selling Stockholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. i Table of C

View Full Filing

View this S-1/A filing on SEC EDGAR